We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study.
- Authors
Burger, Robert A; Sill, Michael W; Monk, Bradley J; Greer, Benjamin E; Sorosky, Joel I
- Abstract
Vascular endothelial growth factor (VEGF) seems to be a promoter of tumor progression for epithelial ovarian cancer (EOC) and primary peritoneal cancer (PPC). We conducted a phase II trial to assess the efficacy and tolerability of single-agent bevacizumab, an anti-VEGF monoclonal antibody.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Vol 25, Issue 33, p5165
- ISSN
1527-7755
- Publication type
Journal Article
- DOI
10.1200/JCO.2007.11.5345